Last reviewed · How we verify
NCT04459741: HISH
HIV, Immune Activation and Salt Sensitive Hypertension
NA trial testing Dietary salt (Sodium chloride) in HIV-1-infection in 85 participants. Completed in 31 December 2019.
31 December 2019
Quick facts
| Lead sponsor | Mulungushi University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 85 |
| Start date | 2 January 2019 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across Zambia |
Drugs / interventions tested
- Dietary salt (Sodium chloride)
Conditions studied
- HIV-1-infection — all drugs for HIV-1-infection →
- Hypertension,Essential — all drugs for Hypertension,Essential →
Sponsor
Mulungushi University
Who can join
Adults 18 to 60, any sex, with HIV-1-infection or Hypertension,Essential. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
High dietary salt is associated with immune activation, elevated levels of inflammatory cytokines and hypertension in murine models. Hypertension is independently associated with inflammation in both murine studies and studies in humans. In people living with HIV, these interactions are not well established. The aim of this study is to determine the effect of excess dietary salt on immune cell activation, pro- and anti-inflammatory cytokines and blood pressure between individuals with and without hypertension among people living with HIV and HIV negative persons.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04459741
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV-1-infection
Currently open trials in the same condition.
- NCT07293559 — Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States · recruiting
- NCT06919016 — A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1- · Phase 1 · active not recruiting
- NCT06554717 — Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV · Phase 2 · recruiting
- NCT06774872 — Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Succes · Phase 2 · recruiting
- NCT06890988 — Ending the Epidemic Interventions in the Dental Setting - UH3 · NA · recruiting
Other Mulungushi University trials
Trials by the same sponsor.
- NCT04844255 — Acute Salt Sensitivity of Blood Pressure · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04459741 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mulungushi University
- Last refreshed: 7 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04459741.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing